Core Viewpoint - MeiHua Bio's stock experienced a decline of 2.07% on November 21, with a trading price of 10.40 CNY per share and a total market capitalization of 29.164 billion CNY [1] Financial Performance - For the period from January to September 2025, MeiHua Bio reported a revenue of 18.215 billion CNY, representing a year-on-year decrease of 2.49%. However, the net profit attributable to shareholders increased by 51.61% to 3.025 billion CNY [2] Shareholder Information - As of September 30, 2025, the number of shareholders for MeiHua Bio reached 66,700, an increase of 13.10% from the previous period. The average number of circulating shares per shareholder decreased by 13.09% to 42,058 shares [2] Dividend Distribution - Since its A-share listing, MeiHua Bio has distributed a total of 12.047 billion CNY in dividends, with 4.075 billion CNY distributed over the past three years [3] Major Shareholders - As of September 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 98.9229 million shares, an increase of 18.3366 million shares from the previous period. New shareholders include Guotai CSI Livestock Breeding ETF and Southern S&P China A-share Large Cap Dividend Low Volatility 50 ETF [3]

证券代码：600873 证券简称：梅花生物 公告编号：2025-056 梅花生物科技集团股份有限公司 关于2025年前三季度经营数据公告 3、 按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 1,286,078.58 | | 国外 | 535,466.15 | | 合计 | 1,821,544.73 | 特此公告。 梅花生物科技集团股份有限公司董事会 2025 年 10 月 29 日 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条相关规定， 现将梅花生物科技集团股份有限公司 (以下简称"公司")2025 年前三季度经营 数据（未经审计）公告如下： 1、 按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 533,112.08 | | 饲料氨基酸（赖氨酸、苏氨酸、饲料级缬氨酸等） | 819,198.33 | | 医药氨基酸（谷氨酰胺、脯氨酸、异亮氨酸、鸟苷、腺苷等） | 46,909.91 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 290,884.73 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for future growth potential [4][6]. Core Insights - The company achieved a revenue of 12.28 billion yuan in H1 2025, a year-on-year decrease of 2.87%, while the net profit attributable to shareholders increased by 19.96% to 1.768 billion yuan [1]. - The company continues to focus on high-quality development in its core amino acid business, with significant project investments and expansions planned [3]. - The company has successfully adapted to global competition, maintaining an export ratio above 30% and effectively responding to anti-dumping measures in the EU [3]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 12.28 billion yuan, a decrease of 2.87% year-on-year, and a net profit of 1.768 billion yuan, an increase of 19.96% [1]. - For Q2 2025, revenue was 6.012 billion yuan, down 2.34% year-on-year, with a net profit of 749 million yuan, up 3.76% year-on-year [1]. Revenue Breakdown - Revenue from flavor enhancers was 3.566 billion yuan, down 8.10% year-on-year; feed amino acids generated 5.660 billion yuan, up 3.44%; and pharmaceutical amino acids brought in 247 million yuan, down 1.18% [2]. Strategic Developments - The company is investing in various projects, including the Tongliao MSG capacity upgrade and the Jilin lysine project, which is expected to commence trial production in Q4 2025 [3]. - The company has successfully completed the acquisition of related food and pharmaceutical amino acid businesses in Japan, enhancing its product line and market reach [3]. Profit Forecast - The projected net profits for 2025, 2026, and 2027 are 3.173 billion yuan, 3.242 billion yuan, and 3.344 billion yuan, respectively, with corresponding EPS of 1.11 yuan, 1.14 yuan, and 1.17 yuan [4][5].

证券代码：600873 证券简称：梅花生物 公告编号：2025-049 梅花生物科技集团股份有限公司 关于2025年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条相关规定， 现将梅花生物科技集团股份有限公司（以下简称"公司"）2025 年半年度经营 数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 356,622.56 | | 饲料氨基酸（赖氨酸、苏氨酸、饲料级缬氨酸等） | 565,978.16 | | 医药氨基酸（谷氨酰胺、脯氨酸、异亮氨酸、鸟苷、腺苷等） | 24,734.04 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 188,930.22 | | 其他（黄原胶、海藻糖等） | 91,780.08 | | 合计 | 1,228,045.06 | 2、按销售模式分： 特此公告。 梅花生物科技集团股份有限公司董事会 ...